Moleculin Biotech, Inc. Operating Income Loss

• Moleculin Biotech, Inc. showed an increase of +5.8% in Operating Income Loss from 2024 to 2025.
• This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Moleculin Biotech, Inc.'s Operating Income Loss has declined by 546.5%.
• Historical annual values: Fiscal year 2025: -$25.10 million | Fiscal year 2024: -$26.64 million | Fiscal year 2023: -$29.63 million | Fiscal year 2022: -$30.64 million | Fiscal year 2021: -$22.97 million | Fiscal year 2020: -$19.74 million | Fiscal year 2019: -$17.52 million | Fiscal year 2018: -$15.03 million | Fiscal year 2017: -$8.65 million | Fiscal year 2016: -$3.88 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026